Posted by Michael Wonder on 03 Nov 2022
Pfizer’s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma
3 November 2022 - Breakthrough therapy designation based on updated data from Phase 2 MagnetisMM-3 study that showed an overall response rate of 61.0% and a manageable safety profile after a median follow-up of 6.8 months.
Pfizer today announced its investigational cancer immunotherapy, elranatamab, received breakthrough therapy designation from the US FDA for the treatment of people with relapsed or refractory multiple myeloma.
